The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Bortezomib-Dexamethasone-Doxorubicin-Study
Official Title: Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure
Study ID: NCT00401804
Brief Summary: The primary objective of the study is to evaluate the activity of BDD in subjects with acute renal failure as measured by· reversal of acute renal failureSecondary objectives· tumor response (complete and partial response)· To evaluate the safety of Bortezomib- Doxorubicin-Dexamethasone in this patient population· to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on progression free survival · to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on overall survival
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Landeskrankenhaus Feldkirch, Feldkirch, , Austria
Klinischen Abteilung für Hämatologie, Medizinische Universitätsklinik Graz, Graz, , Austria
Landeskrankenhaus Leoben, Leoben, , Austria
Dep. of Internal Medicine I, Oncology, SALK - Gemeinnützige Salzburger Landeskliniken, Salzburg, , Austria
Medical University of Vienna, Dep. of Internal Medicine I, Vienna, , Austria
Universitätsklinik für Innere Medizin I, Vienna, , Austria
Wilhelminenspital Vienna, 1st Med. Department - center for Oncology and Hematology, Vienna, , Austria
Klinikum Kreuzschwestern Wels GmbH, Wels, , Austria
FN Brno Interni Hematoonkolog. klinika, Brno, , Czech Republic
Name: Heinz Ludwig, MD, Univ.Prof.
Affiliation: Austrian Forum agianst Cancer; Wilhelminenspital Vienna, 1st. Med. Department - center for Oncology and Hematology
Role: PRINCIPAL_INVESTIGATOR